A Randomised, Double-blind, Three-arm, Single-dose, Parallel Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity Profile of MB09 (Proposed Denosumab Biosimilar) and EU/US-sourced Xgeva in Healthy Male Volunteers
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Pharmacokinetics
- Sponsors mAbxience
Most Recent Events
- 12 Jun 2023 Status changed from active, no longer recruiting to completed.
- 13 Jan 2023 Planned End Date changed from 23 Jan 2023 to 23 Mar 2023.
- 13 Jan 2023 Planned primary completion date changed from 23 Jan 2023 to 23 Mar 2023.